Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00314210 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Maintenance Study of Quetiapine SR to Treat GAD Patients.
A Phase 3 study of Anxiety Disorders, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 575
- Enrollment target
- 20
- Study locations
NCT00314210: Completed Phase 3 study of Anxiety Disorders, sponsored by AstraZeneca.
NCT00314210 is a Phase 3 study of Anxiety Disorders that has completed, run by AstraZeneca. The registered enrollment target is 575 participants, below the 1,133-participant average among 84 other Anxiety Disorders trials with a reported enrollment target (49% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00314210, a Phase 3 study of Anxiety Disorders, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 575 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to evaluate the efficacy of quetiapine SR compared to placebo in increasing time from randomisation to an anxiety event in patients with generalised anxiety disorder (GAD). PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Conditions Studied
Interventions
- DRUG Quetiapine SR
Study Locations (20)
Florida
- Research Site - Coral Springs
- Research Site - DeLand
- Research Site - Fort Myers
- Research Site - Gainsville
- Research Site - Hialeah
- Research Site - Jacksonville
- Research Site - North Miami
- Research Site - Orlando
- Research Site - Saint Petersberg
California
- Research Site - Fresno
- Research Site - La Mesa
- Research Site - Oceanside
- Research Site - Redlands
Georgia
- Research Site - Atlanta
- Research Site - Columbus
- Research Site - Marietta
- Research Site - Roswell
Arizona
- Research Site - Mesa
- Research Site - Peoria
- Research Site - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 575 participants |
| Start Date | 2006-03 |
| Est. Completion | 2007-08 |
| Phase | Phase 3 |
What the finished NCT00314210 record still lists
NCT00314210 is an interventional study that assigns participants to a tested intervention. The registered 575 participants enrollment target is mid-sized for trials with a published cap, below the 1,133-participant average among 84 other Anxiety Disorders trials with a reported enrollment target (49% lower).
The record links to 1 condition, with Anxiety Disorders appearing as the primary indexed condition, and to 1 intervention - of which Quetiapine SR is the first listed.
NCT00314210 names 20 study sites across 4 states, led by Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT00314210 about?
NCT00314210 is a clinical study titled "Safety and Efficacy Maintenance Study of Quetiapine SR to Treat GAD Patients.". The primary objective of this study is to evaluate the efficacy of quetiapine SR compared to placebo in increasing time from randomisation to an anxiety event in patients with generalised anxiety disorder (GAD). PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designat...
What is the current status of trial NCT00314210?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 575 participants. The study started on 2006-03. Estimated completion is 2007-08.
What conditions does trial NCT00314210 study?
This clinical trial studies the following conditions: Anxiety Disorders.
What interventions are being tested in trial NCT00314210?
The interventions under investigation include: Quetiapine SR (DRUG).
Who is sponsoring clinical trial NCT00314210?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00314210 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00314210's enrollment target sits among peer trials
575 13th of 84 higher than 72 of 84 other Anxiety Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anxiety Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder
RECRUITING · Phase 3
-
Fluoxetine vs CBT in Childhood Anxiety Disorders
ACTIVE NOT RECRUITING · Phase 3
-
A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder
COMPLETED · Phase 3
-
Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS
COMPLETED · Phase 3
-
Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD)
COMPLETED · Phase 3
-
Telephone-Based Care Management Program for Individuals With Anxiety Disorders
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02610439 · 575 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer
- NCT05919264 · 575 participants · Phase 1
FOG-001 in Locally Advanced or Metastatic Solid Tumors
- NCT06583148 · 575 participants · NA
A Smoke-Free Home Intervention in Tribal Communities
- NCT06883175 · 575 participants · NA
Evolution of the Chicago Classification: Bridging Physiology and Mechanics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia